InfuSystem Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
InfuSystem Holdings, Inc. (the "Company") filed this Current Report on Form 8-K on March 26, 2015, to disclose the entry into a new material definitive credit agreement and the termination of its prior credit facility. The Company, headquartered in Madison Heights, Michigan, operates in the healthcare industry, specifically providing infusion pumps and related services.
Key Financial Metrics and Debt Structure
The Company entered into a Credit Agreement with JPMorgan Chase Bank, N.A., establishing the following capital structure:
- Term A Loan: $27.0 million (fully drawn on March 23, 2015, to repay the prior Wells Fargo facility).
- Term B Loan: $8.0 million (available for acquisitions; undrawn as of filing).
- Revolving Credit Facility: Up to $10.0 million for general corporate purposes, with a $1.5 million sub-limit for letters of credit.
- Effective Interest Rate: 3.00% as of March 25, 2015.
- Borrowing Base: Approximately $10.0 million as of March 23, 2015, based on eligible accounts and inventory as of December 31, 2014.
- Prepayment Costs: $509,032.86 paid to terminate the prior Wells Fargo facility.
Material Changes Versus Prior Period
The primary material change is the replacement of the existing credit facility with Wells Fargo Bank (the "WF Facility") with the new JPMorgan Chase facility. The Company repaid all outstanding loans under the WF Facility. A letter of credit of approximately $0.3 million from the prior facility was cash collateralized and remains in place pending transfer to the new agreement.
Covenants, Risks, and Outlook
The new Credit Agreement imposes significant financial and operational covenants:
- Financial Covenants: Minimum fixed charge coverage ratio of 1.25:1.00; maximum total leverage ratio ranging from 3.00:1.00 to 2.25:1.00; minimum net worth of $37.5 million.
- Restrictive Covenants: Limitations on incurring additional indebtedness, creating liens, mergers, acquisitions, asset dispositions, dividends, and stock repurchases.
- Security: The Company granted a first priority security interest in substantially all personal property assets and pledged equity interests in its subsidiaries.
- Events of Default: Include non-payment, breach of covenants, bankruptcy, loss of healthcare permits (CMS Certification Number), FDA enforcement actions, and delisting from the NYSE MKT.
- Maturity: All obligations mature on March 23, 2020. Term A Loan requires quarterly principal repayments of $965,000 starting September 30, 2015.
Investor Verification Checklist
- Verify the Company's ability to maintain the minimum fixed charge coverage ratio of 1.25:1.00 and the maximum leverage ratio of 3.00:1.00.
- Confirm the status of the $0.3 million letter of credit previously issued under the Wells Fargo facility and its transfer to the new agreement.
- Monitor the Company's compliance with healthcare regulatory requirements, specifically CMS Certification Numbers and FDA regulations, as their loss constitutes an event of default.
- Review the utilization of the $8.0 million Term B Loan, which is restricted to acquisitions and expires on March 21, 2016, if not drawn.
- Assess the impact of the $965,000 quarterly principal repayment requirement on future cash flows.